Physician profile
William P Murphy
NPI 1659305738
$7,099.40
in general payments reported to CMS, 2019-2025
36 companies · $904 in 2025
The $904 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $379 · 2021: $406 · 2022: $1,072 · 2023: $1,246 · 2024: $1,626 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,776.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $776.76 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $635.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $623.19 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $597.05 | 2019-2025 | |
| Novo Nordisk INC | $534.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $532.36 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.53 | 2019-2023 | |
| Abbvie INC. | $495.89 | 2022-2025 | |
| Amgen INC. | $489.51 | 2019-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $318.16 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $251.39 | 2019-2025 | |
| Indivior INC. | $181.47 | 2019-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $146.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $145.69 | 2021-2025 | Verquvo, Gardasil 9, Vaxneuvance |
| Sumitomo Pharma America, INC. | $116.96 | 2023-2025 | Gemtesa |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.